Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2598-2610

  Alhamoruni, A ^a   Wright, K L ^b   Larvin, M ^a   O'Sullivan, S E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

9 tetrahydrocannabinol and cannabidiol; Caco 2 cells; Cannabinoid CB 1 receptor; Cytokines; Endocannabinoid; Inflammation; Intestinal permeability; Transepithelial electrical resistance (TEER)

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2 CHLORO 5 NITROBENZANILIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABIDIOL; CAPSAZEPINE; DRONABINOL; ENDOCANNABINOID; GAMMA INTERFERON; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; DEGRADATION; DRUG ACTIVITY; DRUG MECHANISM; ELECTRIC RESISTANCE; IN VITRO STUDY; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; PRIORITY JOURNAL; SYNTHESIS;

AMIDOHYDROLASES; BENZAMIDES; BENZODIOXOLES; CACO-2 CELLS; CANNABINOIDS; CARBAMATES; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; INDOLES; INFLAMMATION; INTERFERON-GAMMA; INTESTINES; MONOACYLGLYCEROL LIPASES; PERMEABILITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859051261     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01589.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE (2010). Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther 335: 92-102.
3. Amasheh S, Dullat S, Fromm M, Schulzke JD, Buhr HJ, Kroesen AJ (2009). Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel disease. Int J Colorectal Dis 24: 1149-1156.
4. Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M et al. (1999). Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg 3: 252-262.
5. Barutta F, Corbelli A, Mastrocola R, Gambino R, Di Marzo V, Pinach S et al. (2010). Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 59: 1046-1054.
6. Bruewer M, Samarin S, Nusrat A (2006). Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci 1072: 242-252. (Pubitemid 44448457)
7. Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F et al. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154: 1001-1008. (Pubitemid 351915071)
8. Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MA et al. (2003). Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur J Pharmacol 459: 97-105. (Pubitemid 36050110)
9. Coutts AA, Izzo AA (2004). The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4: 572-579. (Pubitemid 40267871)
10. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S (2002). Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422. (Pubitemid 34569188)
11. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP et al. (1998). In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmaco 125: 1393-1395. (Pubitemid 28548549)
12. Croci T, Landi M, Galzin AM, Marini P (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122. (Pubitemid 37175837)
13. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570. (Pubitemid 46671252)
14. D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, Grandone I et al. (2007). Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 85: 523-530. (Pubitemid 46701662)
15. Di Marzo V, De Petrocellis L (2010). Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 17: 1430-1449.
16. Duncan M, Davison JS, Sharkey KA (2005). Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22: 667-683. (Pubitemid 41475329)
17. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS et al. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol 295: G78-G87.
18. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI (2006). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168: 235-244. (Pubitemid 43062576)
19. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92: 3376-3380.
20. de Filippis D, Iuvone T, d'amico A, Esposito G, Steardo L, Herman AG et al. (2008). Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 20: 919-927.
21. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermuller N et al. (2001). Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol 281: G216-G228.
22. Guagnini F, Valenti M, Mukenge S, Matias I, Bianchetti A, Di Palo S et al. (2006). Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55: 946-953. (Pubitemid 43962605)
23. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL (1992). Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 102: 416-423.
24. Ihenetu K, Molleman A, Parsons ME, Whelan CJ (2003). Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458: 207-215. (Pubitemid 36050722)
25. Izzo AA (2007). The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 19: 704-708.
26. Izzo AA, Camilleri M (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57: 1140-1155.
27. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T et al. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134: 563-570. (Pubitemid 32977900)
28. Kulkarni-Narla A, Brown DR (2000). Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302: 73-80.
29. Lu TS, Avraham HK, Seng S, Tachado SD, Koziel H, Makriyannis A et al. (2008). Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol 181: 6406-6416.
30. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA et al. (2004). TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol 286: G367-G376. (Pubitemid 38250308)
31. Madara JL, Pappenheimer JR (1987). Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. J Membr Biol 100: 149-164. (Pubitemid 18004072)
32. Madara JL, Stafford J, Barenberg D, Carlson S (1988). Functional coupling of tight junctions and microfilaments in T84 monolayers. Am J Physiol 254 (3 Pt 1): G416-G423.
33. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209. (Pubitemid 38544105)
34. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA (2004). Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142: 1247-1254. (Pubitemid 39178878)
35. Morehouse JL, Specian RD, Stewart JJ, Berg RD (1986). Translocation of indigenous bacteria from the gastrointestinal tract of mice after oral ricinoleic acid treatment. Gastroenterology 91: 673-682. (Pubitemid 16045418)
36. Mukhopadhyay P, Pan H, Rajesh M, Bátkai S, Patel V, Harvey-White J et al. (2010). CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br J Pharmacol 3: 657-668.
37. Mukhopadhyay P, Horváth B, Rajesh M, Matsumoto S, Saito K, Bátkai S et al. (2011). Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 50: 179-195.
38. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
39. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B et al. (2009). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 328: 708-714.
40. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
41. Poritz LS, Garver KI, Tilberg AF, Koltun WA (2004). Tumor necrosis factor alpha disrupts tight junction assembly. J Sur Res 116: 14-18. (Pubitemid 38083280)
42. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR et al. (2007). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 293: H610-H619. (Pubitemid 47105122)
43. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S et al. (2010a). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56: 2115-2125.
44. Rajesh M, Mukhopadhyay P, Haskó G, Liaudet L, Mackie K, Pacher P (2010b). Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 160: 688-700.
45. Sanger GJ (2007). Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 152: 663-670.
46. Siegmund SV, Seki E, Osawa Y, Uchinami H, Cravatt BF, Schwabe RF (2006). Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 281: 10431-10438. (Pubitemid 43864582)
47. Unno N, Fink MP (1998). Intestinal epithelial hyperpermeability. Mechanisms and relevance to disease. Gastroenterol Clin North Am 27: 289-307. (Pubitemid 28325383)
48. Wang F, Daugherty B, Keise LL, Wei Z, Foley JP, Savani RC et al. (2003). Heterogeneity of claudin expression by alveolar epithelial cells. Am J Respir Cell Mol Biol 29: 62-70. (Pubitemid 36783317)
49. Wells CL, van de Westerlo EM, Jechorek RP, Haines HM, Erlandsen SL (1998). Cytochalasin-induced actin disruption of polarized enterocytes can augment internalization of bacteria. Infection Immunity 66: 2410-2419. (Pubitemid 28261732)
50. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453. (Pubitemid 41096632)
51. Wright KL, Duncan M, Sharkey KA (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153: 263-270.